Comparative Pharmacology
Head-to-head clinical analysis: QUELICIN versus SUCOSTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUELICIN versus SUCOSTRIN.
QUELICIN vs SUCOSTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depolarizing neuromuscular blocker that binds to nicotinic acetylcholine receptors at the motor end-plate, causing persistent depolarization and preventing repolarization, resulting in neuromuscular blockade.
Succinylcholine is a depolarizing neuromuscular blocker that binds to and activates nicotinic acetylcholine receptors at the neuromuscular junction, causing initial muscle fasciculations followed by prolonged depolarization and receptor desensitization, resulting in neuromuscular blockade.
1 mg/kg IV bolus for rapid sequence intubation; maintenance infusion 0.5-1 mg/min IV for prolonged procedures.
IV: 0.3-1.1 mg/kg initially, then maintenance of 0.04-0.07 mg/kg as needed or continuous infusion of 2.5-4.3 mg/min.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 minutes in normal patients; prolonged to 20-40 minutes in patients with pseudocholinesterase deficiency.
Terminal elimination half-life is approximately 2-4 minutes for succinylcholine (rapid hydrolysis by plasma pseudocholinesterase). In patients with atypical pseudocholinesterase or deficiency, half-life may be prolonged to 20-60 minutes, leading to prolonged paralysis.
Primarily hydrolyzed by plasma pseudocholinesterase; less than 2% excreted unchanged in urine; minimal biliary/fecal elimination.
Primarily renal excretion of unchanged drug and metabolites (succinylmonocholine); minimal biliary/fecal elimination (<2%). Approximately 10-20% excreted unchanged in urine, with the remainder as succinylmonocholine.
Category C
Category C
Neuromuscular Blocker (Depolarizing)
Neuromuscular Blocker (Depolarizing)